Founder,
Chief Executive Officer
Member,
Board of Managers
James Posada, Ph.D., is founder and Chief Executive Officer…
Chairman of the Board of Managers
Dr. Peter Kiener is an experienced veteran in pharmaceutical…
Peter Kiener, PH.D.
Chairman of the Board of Managers
Dr. Peter Kiener is an experienced veteran in pharmaceutical development. He previously served as Chief Scientific Officer of Ambrx Inc., a clinical stage biopharmaceutical company focused on the development of antibody-drug conjugates. Prior, he was President and co-founder of Zyngenia Inc., an early stage biopharmaceutical company. He held leadership roles at MedImmune, including Executive Vice President and Global Head of Biologics Research and Development, Senior Vice President and Head of Global Research, and Vice President of Research. Dr. Kiener began his career at the University of North Texas/Texas College of Osteopathic Medicine, where he was an Assistant Professor, and the University of Massachusetts at Amherst, where he was a Research Associate. Dr. Kiener has served on the scientific advisory boards of KAI Pharmaceuticals Inc., Genocea Biosciences Inc., NKT Therapeutics Inc. and VLST Corporation. He has published more than 120 papers in peer-reviewed journals, and is an inventor on more than 40 patents and patent applications. Dr. Kiener earned a Bachelor’s degree in chemistry from the University of Lancaster and a Doctorate of Philosophy in biochemistry from the University of Oxford.
Member, Board of Managers
Somu Subramaniam, Member, Board of Managers
Somu Subramaniam
Member, Board of Managers
Somu Subramaniam is the co-founder and Managing Partner of New Science Ventures. Prior to founding NSV, Somu was a director at McKinsey & Company where he advised leading multinational companies in the pharmaceuticals, medical devices, biotechnology, photonics, software and semiconductor industries. At McKinsey, Somu was leader of the Strategy Practice, the Technology Practice, the Biotechnology Group, and the Healthcare Practice. He also served on the firm’s Investment Committee and led its Equity Portfolio Committee. Somu holds a B.Tech. degree from the Indian Institute of Technology and an M.B.A. from Harvard Business School.